NATCO Pharma Ltd.
NSE: NATCOPHARMNATCO Pharma Ltd.: A 30-second snapshot
Natco Pharma (₹933) is a mid-cap generic pharma company that has seen revenue contract 39.6% and earnings decline 34.1% over five years, with FY26 results further disappointing — triggering a 15% single-session sell-off on 29 May 2026. Trailing PE of 11.8 is the lowest among the six sector peers tracked, while debt-to-equity of 7.74 is sharply elevated versus pharma-sector norms, and management has guided for a revenue recovery resuming only from FY28.
P/E
11.8
Forward P/E
20.5
ROE
+16.9%
Debt / Equity
7.74
Profit Margin
+34.8%
Div. Yield
+0.6%
5Y ROE > 15%
3/5
5Y FCF > 0
4/5
Quality
47/100
News
7 headlines · 1 positive · 2 negative
Natco Pharma shares slump 15% after Q4 results; here's why the stock is falling - Business Today
Business Today
NATCOPHARM: FY26 revenue and profit declined year-over-year, with a one-time tax gain and key acquisition impact - TradingView
TradingView
NATCOPHARM: Revenue and profit declined in FY26, but growth is expected to resume from FY28 - TradingView
TradingView
NATCOPHARM: FY 2026 saw lower profits and revenue, but diversification and new launches set up future growth - TradingView
TradingView
Natco Pharma Limited Provides Earnings Guidance for 2027 - marketscreener.com
marketscreener.com
Recent context
- ·On 29 May 2026, Natco Pharma shares fell approximately 15% following FY26 results that showed year-over-year declines in both revenue and profit; the company disclosed a one-time tax gain and the impact of a key acquisition in the reported numbers (TradingView, 29 May 2026).
- ·Management provided FY27 earnings guidance (marketscreener.com, 29 May 2026) and separately indicated that revenue and profit growth is expected to resume from FY28, implying FY27 will also reflect transition-year pressures before the recovery materialises.
- ·Analyst coverage of 9 analysts yields a mean rating of 2.6 on a 1–5 scale (lower = more constructive), placing consensus closer to the constructive end of the scale but with meaningful dispersion given the FY26 miss and extended recovery timeline.
Strengths
- +Profit margin of 34.78% is notably high for a generic pharma company, indicating strong pricing power or a differentiated product mix even in a period of declining absolute revenues.
- +ROE of 16.85% has exceeded 15% in 3 of available historical years, with a consistency score of 70 — moderate persistence for a sector where many peers report sub-15% ROE; Cipla (11.74%) and Dr. Reddy's (11.84%) both trail this level.
- +Trailing PE of 11.8 is ranked cheapest of 6 sector peers, where the next-cheapest (Dr. Reddy's at 25.6) trades at a 2.2x premium — relative valuation compression is at a multi-year low versus peers.
- +FCF was positive in 4 of the available historical years, and the quality consistency score of 70 indicates that the business has historically generated cash, providing some buffer against the current elevated D/E of 7.74.
Weaknesses
- −Revenue has contracted 39.6% and earnings 34.1% over five years — a sustained multi-year decline that goes beyond a single off-year and raises questions about the durability of the core revenue base.
- −Debt-to-equity of 7.74 is materially above pharma-sector norms and the debt trend is marked as rising; combined with declining earnings, interest coverage is under pressure and the leverage position is a primary solvency watch point.
- −FY26 results disappointed versus market expectations, with both revenue and profit declining year-over-year; management has guided that growth will resume only from FY28, meaning near-term earnings are unlikely to close the gap between trailing PE (11.8) and forward PE (20.5).
- −Quality score of 44 ranks 2nd of 6 peers in the dataset, but Sun Pharma (59) leads on this metric while the absolute score of 44 reflects only moderate operational consistency across the measured dimensions.
Open questions
- ?Does the 34.78% profit margin in a period of declining revenue reflect a genuinely differentiated product or licensing portfolio, or is it a function of one-time items that may not persist through FY27–28?
- ?If management's FY28 recovery timeline proves accurate, what level of earnings would be required to justify the current forward PE of 20.5, and how does that compare to the pre-decline earnings peak?
- ?With D/E at 7.74 and rising, what FCF generation is required annually to prevent further leverage deterioration — and does the acquisition referenced in FY26 results improve or worsen that trajectory?
- ?The trailing PE of 11.8 is the lowest among sector peers by a wide margin: does this discount reflect a temporary earnings trough or a more permanent re-rating of the company's competitive position within Indian generics?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| NATCOPHARM | NATCO Pharma Ltd.You're viewing | 11.8 | +16.9% | 44 |
| Industry avg | across 5 peers | 43.2 | +14.8% | 36 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 37.5 | +14.7% | 59 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 60.1 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 63.5 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 28.9 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 25.6 | +11.8% | 17 |
Technical state
Current price
₹933.30
SMA 50
₹1,090.30
SMA 200
₹925.83
RSI (14)
25.8 (oversold)
From 52w high
-23.9%
1Y return
+8.9%
3M return
-4.0%
50-DMA
Below
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highRevenue declined 39.6% and earnings declined 34.1% over 5 years — a sustained multi-year contraction that is atypical for a mid-cap pharma company and indicates structural revenue headwinds, not merely a cyclical trough.
- highDebt-to-equity of 7.74 is far above pharma-sector norms; with a rising debt trend, FCF positive in only 4 of available years, and multi-year earnings decline, leverage coverage is a material solvency watch point.
- mediumRSI at 25.79 is in deeply oversold territory; price is 14.4% below the 50-DMA (₹1,090) though marginally above the 200-DMA (₹925.83) at ₹933. Down 23.9% from the 52-week high.
- mediumFY26 results triggered a 15% single-session decline (Business Today, 29 May 2026); both revenue and profit fell year-over-year in FY26, with management guidance suggesting a recovery timeline extending to FY28 — a gap of nearly two fiscal years.
- mediumForward PE of 20.5 is nearly double the trailing PE of 11.8, implying the market is pricing a meaningful earnings step-up; given the 5-year earnings contraction of 34.1%, the expansion embedded in the forward multiple is not supported by recent trend.
Cross-section contradictions
- Trailing PE of 11.8 ranks lowest among 6 sector peers (1st of 6 — cheapest), yet the stock has delivered +8.9% over 12 months against a 34.1% decline in 5-year earnings — low relative valuation persisting through a multi-year earnings contraction is difficult to reconcile without a clear catalyst for imminent recovery.
- News flow is net negative (2 negative vs 1 positive of 7 articles, triggered by a weak Q4 result), yet the stock remains marginally above its 200-DMA (₹933 vs ₹925.83) — price has not fully given back the level despite earnings pressure.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 1 Jun 2026 · rotates through NIFTY 500 every ~5 days